News | Oncology Related Products | May 06, 2016

Study Finds Breast Cancer Adjuvant Therapy Benefits Vary Over Time

Therapies completed years ago may not keep covering survivors

breast cancer, adjuvant therapy, clinical study, University of Texas Health Science Center

May 6, 2016 — After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy and endocrine drugs to reduce the risk of the cancer returning. It's been assumed that the treatment effects of these therapies remain constant over time, but a new study from the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio suggests the opposite is true.

The study, published in the Journal of the National Cancer Institute, looked at 19 breast cancer adjuvant therapy clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Therapies were evaluated for relative benefit, defined as the percentage by which they reduced recurrence and death among study participants.

Researchers found time-varying treatment effects of adjuvant therapies in nearly half of the trials (nine of 19). "In some trials, the benefit diminished at specific points of time after surgery," said study senior author Ismail Jatoi, M.D., Ph.D., FACS. "In other trials, there was no benefit early on, but then there was a delayed benefit that emerged more than one year after surgery."

In one clinical trial, the researchers found that a regimen provided initial benefit, but then a subsequent disadvantage, to patients, he said. Jatoi is the Dale H. Dorn Chair in Surgery in the School of Medicine at the UT Health Science Center, and serves as professor and chief of the Division of Surgical Oncology and Endocrine Surgery.

The findings may change the way oncologists talk to their patients about effects of treatments they are receiving, Jatoi said.

"We are seeing more and more long-term survivors of breast cancer who had these treatments many years ago," he said. "The question is, if these treatment effects have waned, should we consider extended adjuvant treatment regimens for the long term in some patients."

Adjuvant therapy trials should be designed and interpreted with this in mind, he added.

In 2011, Jatoi wrote a viewpoint article published in the Journal of Clinical Oncology in which he proposed that treatment effects of adjuvant therapy regimens might vary over time. He approached the NSABP, one of the nation's largest clinical trials groups, about doing a study.

NSABP statisticians Hanna Bandos, Ph.D., and Jong Hyeon Jeong, Ph.D., conducted much of the work and are co-authors of the study.

For more information: www.jnci.oxfordjournals.org

Related Content

Lunit Receives Korea MFDS Approval for Lunit Insight MMG
News | Artificial Intelligence | August 19, 2019
Lunit has announced Korea Ministry of Food and Drug Safety (MFDS) approval of its artificial intelligence (AI) solution...
Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging

Image courtesy of Imago Systems

News | Mammography | August 14, 2019
Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year...
Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses
News | Artificial Intelligence | August 13, 2019
University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that...
Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS
News | PACS | August 09, 2019
Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and...
Volpara to Distribute Screenpoint Medical's Transpara AI Solution
News | Breast Imaging | August 02, 2019
Volpara Solutions and ScreenPoint Medical BV signed an agreement under which Volpara will sell ScreenPoint's Transpara...
Ikonopedia Releases Automated Combined Reporting Package at AHRA
News | Mammography Reporting Software | July 26, 2019
Ikonopedia showcased its recently released Automated Combined Reporting package and its entire suite of structured...
Hologic Partners With MagView to Develop Unifi EQUIP Solution
Technology | Mammography Reporting Software | July 25, 2019
Hologic announced a partnership with mammography information solutions provider MagView to develop Unifi EQUIP, an...
Fujifilm Releases Tomosynthesis Biopsy Option for Aspire Cristalle Mammography System
Technology | Breast Biopsy Systems | July 24, 2019
Fujifilm Medical Systems U.S.A. Inc. recently expanded its breast imaging solutions with the launch of its...
IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017.

IBM collected a dataset of 52,936 images from 13,234 women who underwent at least one mammogram between 2013 and 2017, and who had health records for at least one year prior to the mammogram. The algorithm was trained on 9,611 mammograms. Image courtesy of Radiology.

Feature | Artificial Intelligence | July 19, 2019 | Michal Chorev
Breast cancer is the global leading cause of cancer-related deaths in women, and the most commonly diagnosed cancer...
Paragon Biosciences Launches Qlarity Imaging to Advance FDA-cleared AI Breast Cancer Diagnosis System

Qlarity Imaging’s software is used to assist radiologists in the assessment and characterization of breast lesions. Imaging features are synthesized by an artificial intelligence algorithm into a single value, the QI score, which is analyzed relative to a database of reference abnormalities with known ground truth. Image courtesy of Business Wire.

Technology | Artificial Intelligence | July 18, 2019
Paragon Biosciences LLC announced the launch of its seventh portfolio company, Qlarity Imaging LLC, which was founded...